» Articles » PMID: 19472013

SDF-1alpha G801A Polymorphism Predicts Lymph Node Metastasis in Stage T3 Colorectal Cancer

Overview
Journal Ann Surg Oncol
Publisher Springer
Specialty Oncology
Date 2009 May 28
PMID 19472013
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The SDF-1/CXCR4 axis plays an important role in cancer metastasis. SDF1alpha genetic polymorphisms, including SDF1alpha-G801A, have been associated with increased cancer risk and may be predictive of distant metastasis. The present study compared the frequency of 6 SDF1alpha single-nucleotide polymorphisms (SNPs) in patients with colorectal cancer (CRC) with and without lymph node (LN) metastasis and determined whether fibroblasts with different SDF-1alpha genotypes influenced cancer cell proliferation and migration.

Methods: The study enrolled 424 patients with primary T3 stage CRC, with and without lymph node metastasis, and a median follow-up of 48 months. The polymerase chain reaction-sequence specific primers (PCR-SSP) technique was used to identify polymorphisms. Fibroblasts were harvested from 14 patients with stage II CRC and fibroblast-mediated enhancement of cancer cell proliferation and migration was evaluated.

Results: Only the SDF1alpha-G801A polymorphism was associated with LN metastasis. The frequency of GA/AA genotypes was significantly higher in patients with LN metastasis (54.8%) than in patients without LN metastasis (40.7%). In the latter group, disease-free survival was shorter in patients with the GA/AA genotype (74%) than in patients with the GG genotype (87.6%). In patients with LN metastasis, disease-free survival was similar regardless of genotype. Expression of SDF-1alpha mRNA in GA/AA fibroblasts was three times that in GG fibroblasts. GA/AA (but not GG) fibroblasts enhanced colon cancer cell (HCT116) proliferation and migration. These effects were blocked by an SDF-1alpha neutralizing antibody.

Conclusions: The SDF1alpha-G801A polymorphism may increase expression of SDF-1alpha mRNA and be a predictive marker of lymph node metastasis in colorectal cancer.

Citing Articles

Systemic Delivery of an Adjuvant CXCR4-CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy.

Alghamri M, Banerjee K, Mujeeb A, Mauser A, Taher A, Thalla R ACS Nano. 2022; 16(6):8729-8750.

PMID: 35616289 PMC: 9649873. DOI: 10.1021/acsnano.1c07492.


CXCL12/CXCR4 axis gene variants contribute to an increased vulnerability to HPV infection and cervical oncogenesis.

Okuyama N, Cezar-Dos-Santos F, Trugilo K, Esposito A, Guembarovski R, Couto-Filho J J Cancer Res Clin Oncol. 2022; 148(4):793-802.

PMID: 35083551 DOI: 10.1007/s00432-021-03884-0.


Potential Role of CXCR4 Targeting in the Context of Radiotherapy and Immunotherapy of Cancer.

Eckert F, Schilbach K, Klumpp L, Bardoscia L, Sezgin E, Schwab M Front Immunol. 2019; 9:3018.

PMID: 30622535 PMC: 6308162. DOI: 10.3389/fimmu.2018.03018.


The CXCL12 rs1801157 polymorphism and risk of colorectal cancer: a meta-analysis.

Xu K, Dai H, Wang S, Zhang J, Liu T Onco Targets Ther. 2018; 11:2445-2452.

PMID: 29760554 PMC: 5937488. DOI: 10.2147/OTT.S151514.


Association of rs1801157 single nucleotide polymorphism of CXCL12 gene in breast cancer in Pakistan and expression analysis of CXCL12-CXCR4 associated biological regulatory network.

Khalid S, Hanif R PeerJ. 2017; 5:e3822.

PMID: 28929029 PMC: 5602684. DOI: 10.7717/peerj.3822.